Results 11 to 20 of about 3,273,257 (269)

Anticholinergic therapy for acute asthma in children. [PDF]

open access: yes, 2012
Inhaled anticholinergics as single agent bronchodilators (or in combination with beta(2)-agonists) are one of the several medications available for the treatment of acute asthma in ...
Beakes   +49 more
core   +2 more sources

Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease [PDF]

open access: yes, 2013
The aim of the study was to characterize pharmacokinetics of tiotropium solution 5 µg compared to powder 18 µg and assess dose-dependency of tiotropium solution pharmacodynamics in comparison to placebo.
Cornelissen, PJG   +7 more
core   +1 more source

Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? [PDF]

open access: yes, 2014
The authors acknowledge the medical writing assistance received from Sam Yarwood, PhD, of Complete HealthVizion, in the form of literature searches and preparation and revision of the draft manuscript.Peer reviewedPublisher ...
Fromer, Leonard   +4 more
core   +10 more sources

Paediatrics: how to manage acute asthma exacerbations

open access: yesDrugs in Context, 2021
Background: Asthma is the most common chronic disease of childhood and a major source of childhood health burden worldwide. These burdens are particularly marked when children experience characteristic ‘symptom flare-ups’ or acute asthma exacerbations ...
James S Leung
doaj   +1 more source

Bronchodilator Response in Patients with Persistent Allergic Asthma Could Not Predict Airway Hyperresponsiveness

open access: yesAllergy, Asthma & Clinical Immunology, 2007
Anticholinergics, or specific antimuscarinic agents, by inhibition of muscarinic receptors cause bronchodilatation, which might correlate with activation of these receptors by the muscarinic agonist methacholine.
Petanjek Bojana B   +3 more
doaj   +1 more source

COPD and cardiovascular disease [PDF]

open access: yes, 2019
COPD is one of the major public health problems in people aged 40 years or above. It is currently the 4th leading cause of death in the world and projected to be the 3rd leading cause of death by 2020.
André, S.   +5 more
core   +3 more sources

Oxygen versus air-driven nebulisers for exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial

open access: yesBMC Pulmonary Medicine, 2018
Background In exacerbations of chronic obstructive pulmonary disease, administration of high concentrations of oxygen may cause hypercapnia and increase mortality compared with oxygen titrated, if required, to achieve an oxygen saturation of 88–92 ...
George Bardsley   +7 more
doaj   +1 more source

Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety

open access: yesTherapeutic Advances in Respiratory Disease, 2015
The international guidelines on chronic obstructive pulmonary disease (COPD) recommend inhaled bronchodilators for maintenance treatment of the disease. These drugs include β2-agonists and muscarinic antagonists, which are both available as short-acting ...
Erminia Ridolo   +4 more
doaj   +1 more source

Association between body composition, sarcopenia and pulmonary function in chronic obstructive pulmonary disease

open access: yesBMC Pulmonary Medicine, 2022
Background Chronic Obstructive Pulmonary Disease (COPD) is characterized by progressive and irreversible airflow limitation. Different factors that modify pulmonary function include age, sex, muscular strength, and a history of exposure to toxic agents ...
Nathalie Martínez-Luna   +9 more
semanticscholar   +1 more source

Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. [PDF]

open access: yes, 2014
BACKGROUND: Inhaled corticosteroids (ICS) are anti-inflammatory drugs that have proven benefits for people with worsening symptoms of chronic obstructive pulmonary disease (COPD) and repeated exacerbations.
Agarwal   +163 more
core   +1 more source

Home - About - Disclaimer - Privacy